0001104659-23-129716.txt : 20231227 0001104659-23-129716.hdr.sgml : 20231227 20231227160204 ACCESSION NUMBER: 0001104659-23-129716 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20231227 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231227 DATE AS OF CHANGE: 20231227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NKGen Biotech, Inc. CENTRAL INDEX KEY: 0001845459 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40427 FILM NUMBER: 231517962 BUSINESS ADDRESS: STREET 1: 3001 DAIMLER ST, CITY: SANTA ANA STATE: CA ZIP: 92705 BUSINESS PHONE: (949) 396-6830 MAIL ADDRESS: STREET 1: 3001 DAIMLER ST, CITY: SANTA ANA STATE: CA ZIP: 92705 FORMER COMPANY: FORMER CONFORMED NAME: Graf Acquisition Corp. IV DATE OF NAME CHANGE: 20210210 8-K 1 tm2333801d1_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 27, 2023

NKGen Biotech, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40427		86-2191918
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3001 Daimler Street

Santa Ana, CA, 92705

(Address of principal executive offices and zip code)

Registrant’s telephone number, including area code: (949) 396-6830

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		NKGN		Nasdaq Global Market

Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share		NKGNW		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 8.01. Other Events.

On December 27, 2023, NKGen Biotech, Inc. (the “Company”) issued a press release announcing that it has received a No Objection Letter from Health Canada for its Clinical Trial Application for a Phase 1/2a study to evaluate the safety, tolerability, and exploratory efficacy of SNK01 natural killer cell therapy for treatment of patients with moderate Alzheimer’s Disease. A copy of the press release is attached as Exhibit 99.1 to this report.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.		Description
99.1		Press release, dated December 27, 2023
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	NKGEN BIOTECH, INC.

Date: December 27, 2023	/s/ Paul Y. Song
	Name:	Paul Y. Song
	Title:	Chief Executive Officer (Principal Executive Officer)

EX-99.1 2 tm2333801d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

NKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease

NKGen’s SNK01 program continues to show positive progress with the FDA IND clearance in October 2023, and now the CTA clearance by Health Canada for a phase 1/2a clinical trial in moderate Alzheimer’s Disease patients.

Based on data generated from its Phase I dose escalation safety trial, presented at the recent CTAD conference in October 2023, NKGen is optimistic that the Phase 1/2a clinical trial could demonstrate more pronounced cognitive benefits and a greater decrease in neuroinflammation.

The U.S. Phase 1/2a trial of SNK01 in moderate Alzheimer’s disease patients offically opened with first patient enrolled in December 2023.

SANTA ANA, Calif., December 27, 2023 -- NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics, today announced that it has received a No Objection Letter (“NOL”) from Health Canada for its Clinical Trial Application (“CTA”) for a Phase 1/2a study to evaluate the safety, tolerability, and exploratory efficacy of SNK01 natural killer (“NK”) cell therapy for treatment of patients with moderate Alzheimer’s Disease (“AD”). SNK01 is an autologous, non-genetically modified NK cell product that has enhanced cytotoxicity and activating receptor expression.

Phase 1 is an open label safety evaluation to determine the maximum tolerated dose and/or recommended Phase 2 dose of SNK01. Phase 2 is a randomized, placebo controlled, multicenter trial evaluating the safety and efficacy of SNK01 in moderate AD patients. This approved trial of approximately 36 patients with moderate AD is expected to commence in December 2023, with the first interim data expected in Q3 2024.

NKGen’s SNK01 program continues to show positive progress in Alzheimer’s Disease, as demonstrated by the most recent results reported at the Clinical Trials on Alzheimer’s Disease (“CTAD”) Annual Meeting in October 2023. Data from a Phase 1, 3 + 3 dose-escalation trial of SNK01 in patients with AD, suggested that SNK01 was well tolerated, and appeared to cross the blood-brain barrier to have a positive effect on brain protein aggregates as well as on neuroinflammation without any related serious adverse effects observed. 90% of patients demonstrated improvement or maintained stable cognitive function as per Alzheimer's disease composite score (“ADCOMS”) at 11 weeks (one week after the last dose).

“It is estimated that more than 350 people in Canada develop some form of dementia each day. We believe the CTA clearance by Health Canada further validates the potential of our neurodegenerative disease program to help address this growing problem,” said Paul Y. Song, M.D., Chief Executive Officer of NKGen Biotech. “While the main focus of existing therapeutics continues to be on individuals with mild cognitive impairment, Health Canada has granted us the opportunity to direct our endeavors towards a more advanced population currently lacking any approved disease modifying therapy. Based on data generated from our Phase I dose escalation safety trial, presented at the recent CTAD conference, we are optimistic that our upcoming Phase 1/2a clinical trial (which incorporates a higher dose and more prolonged dosing schedule), might lead to greater cognitive benefits and a larger reduction in neuroinflammation and proteins.”

About NKGen Biotech

NKGen is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer cell therapeutics. NKGen is headquartered in Santa Ana, California, USA. For more information, please visit www.nkgenbiotech.com.

Forward-Looking Statements

Certain statements made in this press release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “could”, “continue”, “expect”, “estimate”, “may”, “plan”, “outlook”, “future” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward looking statements are subject to risks and uncertainties, many of which are outside of the Company’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Forward looking statements include, but are not limited to, statements regarding the Company’s plans for developing SNK01, including the expected timing of announcing further results from its ongoing Phase 1 clinical trial; the Company’s plans for a Phase 1/2a clinical trial and expectations that the Phase 1/2a clinical trial may show greater cognitive benefit and further reduction in neuroinflammation; the expected trial design for the Phase 1/2a clinical trial; and potential benefits of the Company’s product candidates.

Risks that contribute to the uncertain nature of the forward-looking statements include: the Company’s ability to execute its plans and strategies; risks related to performing clinical studies; the risk that initial and interim results of a clinical trial do not necessarily predict final results and that one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data become available; the FDA’s clearance of the Company’s IND for its Phase 1/2a clinical trial should not be relied on as a validation of SNK01’s potential or the Company’s approach; Health Canada’s clearance of the Company’s CTA for its Phase 1/2a clinical trial should not be relied on as a validation of SNK01’s potential or the Company’s approach potential delays in the commencement, enrollment and completion of clinical studies and the reporting of data therefrom; the risk that studies will not be completed as planned; and NKGen’s ability to raise additional funding to complete the development of its product candidates. These forward-looking statements are based upon NKGen’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. The foregoing list of factors is not exhaustive. These and other risks and uncertainties are described more fully under the caption “Risk Factors” and elsewhere in the Company’s filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on the Company’s website under the subheading “Investors”. Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. You should read this press release completely and with the understanding that the Company’s actual future results or performance may be materially different from what we expect.

Contacts:

Internal Contact:

Denise Chua, MBA, CLS, MT (ASCP)

Vice President, Investor Relations and Corporate Communications

949-396-6830

dchua@nkgenbiotech.com

External Contacts:

Chris Calabrese

Managing Director

LifeSci Advisors, LLC

ccalabrese@lifesciadvisors.com

Kevin Gardner

Managing Director

LifeSci Advisors, LLC

kgardner@lifesciadvisors.com

EX-101.SCH 3 gfor-20231227.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 gfor-20231227_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 gfor-20231227_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Class of Stock [Axis] Common Stock [Member] Warrant [Member] Statement [Table] Document Information [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 gfor-20231227_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2333801d1_ex99-1img001.jpg GRAPHIC begin 644 tm2333801d1_ex99-1img001.jpg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end XML 8 R1.htm IDEA: XBRL DOCUMENT

Cover	Dec. 27, 2023
Document Information [Line Items]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Dec. 27, 2023
Entity File Number	001-40427
Entity Registrant Name	NKGen Biotech, Inc.
Entity Central Index Key	0001845459
Entity Tax Identification Number	86-2191918
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3001 Daimler Street
Entity Address, City or Town	Santa Ana
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92705
City Area Code	949
Local Phone Number	396-6830
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Common Stock [Member]
Document Information [Line Items]
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	NKGN
Security Exchange Name	NASDAQ
Warrant [Member]
Document Information [Line Items]
Title of 12(b) Security	Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share
Trading Symbol	NKGNW
Security Exchange Name	NASDAQ

XML 9 tm2333801d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001845459 2023-12-27 2023-12-27 0001845459 us-gaap:CommonStockMember 2023-12-27 2023-12-27 0001845459 us-gaap:WarrantMember 2023-12-27 2023-12-27 iso4217:USD shares iso4217:USD shares false 0001845459 8-K 2023-12-27 NKGen Biotech, Inc. DE 001-40427 86-2191918 3001 Daimler Street Santa Ana CA 92705 949 396-6830 false false false false Common Stock, $0.0001 par value per share NKGN NASDAQ Warrants, each whole warrant exercisable for one share of Common Stock at an exercise price of $11.50 per share NKGNW NASDAQ true false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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�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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 3 23 1 false 2 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://gfor.grafacq.com/role/Cover Cover Cover 1 false false All Reports Book All Reports gfor-20231227.xsd gfor-20231227_def.xml gfor-20231227_lab.xml gfor-20231227_pre.xml tm2333801d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2333801d1_8k.htm": { "nsprefix": "gfor", "nsuri": "http://gfor.grafacq.com/20231227", "dts": { "schema": { "local": [ "gfor-20231227.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "gfor-20231227_def.xml" ] }, "labelLink": { "local": [ "gfor-20231227_lab.xml" ] }, "presentationLink": { "local": [ "gfor-20231227_pre.xml" ] }, "inline": { "local": [ "tm2333801d1_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 2, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 3, "entityCount": 1, "segmentCount": 2, "elementCount": 65, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 26 }, "report": { "R1": { "role": "http://gfor.grafacq.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333801d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-27", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2333801d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Statement [Table]" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://gfor.grafacq.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-23-129716-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-129716-xbrl.zip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end